#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Millendo appoints director, names chairperson of the board

Share on Twitter Share on LinkedIn
Staff writer | Ann Arbor, Mich., USA | June 24, 2016
MillendoJune 24, 2016, Ann Arbor, Mich., USA - Millendo Therapeutics, Inc., a developer of novel therapies for endocrine diseases, appoints James Hindman as an independent board member and chairperson of its audit committee.
Mr. Hindman most recently served as Executive Vice President of Finance and Business Development and Chief Financial Officer at Allergan, Inc..

Mr. Hindman was also instrumental in facilitating the company’s largest restructuring, that ultimately led to Actavis’ acquisition of Allergan in 2015 and the creation of one of the top ten global pharmaceutical firms.

During his 30-year tenure at Allergan, Mr. Hindman held various senior leadership positions including Executive Vice President of Finance and Business Development and Chief Financial Officer, and Senior Vice President, Finance and Controller, and was responsible for strategic and financial functions including treasury, investor relations, risk, controller, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning.

Additionally, he served as President of the Allergan Foundation from 2009-2015.

Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves as Director of NeuroSigma, Inc. and is a member of the Loyola Marymount University Board of Trustees.

In addition, Millendo has appointed current board member and Partner of New Enterprise Associates, Inc., Carol Gallagher, Pharm.D., as Chairperson of the Board.